Business Insights, Feb 2010, Pages: 154
Pharma,
-Pearl Therapeutics,
-Prosonix,
-Respirics,
-Skye Pharma,
-Vectura Group, DeliveringOpportunities in the InhalableDrugs Market: Innovative formulations and devices
Greystone Associates, May 2009, Pages: 100
Deliveringdrugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS therapeuticdrugs via inhalation mitigates several
Business Insights, Oct 2011, Pages: 92
, pulmonary, and transdermal drug delivery and assess which will be most suitable for you.
Highlights:
- Novel formulations deliver superior returns on investments: drug delivery-based product development
Cientifica Ltd., Sep 2007, Pages: 301
will provide an in-depth discussion on recent developments of nanoparticleenabled drug delivery systems (DDS) and future opportunities. It is tailored for investors who plan to invest in the pharmaceutical
Business Insights, June 2007, Pages: 129
in March 2007 47
Table 3.8: Bionaut’s development pipeline 52
Table 3.9: DanioLab’s development pipeline 53
Table 3.10: Repositioning companies with a therapeutic focus 55
Table 3.11: Opportunities for drug
Business Insights, Nov 2006, Pages: 137
’s inhaled insulin, Exubera, gaining US approval in January 2006.
‘Innovation in Drug Delivery’ provides an in-depth examination of product launches and pipeline drugs with novel drug delivery mechanisms set
PharmaVision, March 2009, Pages: 147
Figure 35: Annual growth of pharmaceutical and biopharmaceutical market, 2004-2011 132
Figure 36: Global sales of 100 best selling drugs 2007& 2012 133
Figure 37: New therapeutics entering clinical study
GlobalData, Dec 2010, Pages: 16
Transave, Inc. - Strategic SWOT Analysis Review
Summary
Transave, Inc. (Transave) is a privately held biopharmaceutical company engaged in the development of inhaled pharmaceuticals for the site
Global Markets Direct, March 2009, Pages: 135
United Sates Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2015
Summary
This report is an essential source for in-depth information and data relating to the US drug
GlobalData, Sep 2011, Pages: 43
and commercialization of drugsdelivered by inhalation for treating severe respiratory diseases by pulmonologists. It has developed a pulmonary drug delivery platform, AERx, which can be customized for the delivery
GlobalData, Sep 2011, Pages: 41
and patent litigation support services. Taifuno is the company’s InhalationDrug Delivery Platform. The company's lead product, Fentanyl TAIFUN is a fast-acting fentanyl formulation, delivered using
GlobalData, Aug 2010, Pages: 30
Akela Pharma Inc., (Akela) is an integrated product development company focused on developing drug delivery technologies and therapeutics for the pain market. It also provides
